FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Vernon

Research Profile

Organizations

Geographic Areas

United States

Concepts & Ideas

Activities & Behaviors

Occupations

Pharmacogenetics

Procedures

Chemicals & Drugs

Pharmaceutical Preparations

Co-author Network

Publications

TOP 3
John Vernon; Joseph H Golec
Correctly measuring drug development risk: a public policy imperative.
John Vernon; Joseph H Golec; Joseph A Dimasi
Drug development costs when financial risk is measured using the Fama-French three-factor model.
John Vernon; Joseph H Golec; J Stedman Stevens
Comparative effectiveness regulations and pharmaceutical innovation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Vernon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: John Vernon; Joseph H Golec
Correctly measuring drug development risk: a public policy imperative.
Expert review of pharmacoeconomics & outcomes research 2011;11(1):1-3.
2010: John Vernon; Joseph H Golec; Joseph A Dimasi
Drug development costs when financial risk is measured using the Fama-French three-factor model.
Health economics 2010;19(8):1002-5.
2010: John Vernon; Joseph H Golec; J Stedman Stevens
Comparative effectiveness regulations and pharmaceutical innovation.
PharmacoEconomics 2010;28(10):877-87.
2010: Joseph Golec; John Vernon
Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
PharmacoEconomics 2010;28(8):615-28.
2010: Antonio Jose Trujillo; Thomas A Mroz; Claudia Piras; John Vernon; Gustavo Angeles
Determinants of gender differences in health among the elderly in Latin America.
World health & population 2010;11(3):24-43.
2010: Patricia A Deverka; John Vernon; howard mcleod
Economic opportunities and challenges for pharmacogenomics.
Annual review of pharmacology and toxicology 2010;50():423-37.
2010: Tejinder K Rakhra-Burris; Todd Auman; Patricia A Deverka; Lynn Dressler; James P Evans; Richard M Goldberg; Tammy M Havener; Janelle M Hoskins; Daniel Jonas; Kevin M Long; Alison A Motsinger-Reif; William Irvin; Kristy Richards; Mary Roederer; John M Valgus; Marcia van Riper; John Vernon; William C Zamboni; Michael J Wagner; Christine M Walko; Karen E Weck; Timothy Wiltshire; howard mcleod
Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.
Pharmacogenomics 2010;11(1):13-21.
2009: John Vernon; Michael Payette; Abhishek Chatterjee
Social welfare and adolescent vaccination programs in the United States: the economic opportunities for a systematic expansion.
Social work in public health 2009;24(5):414-45.
2009: Antonio Jose Trujillo; John Vernon; Laura Rodriguez Wong; Gustavo Angeles
Race and health disparities among seniors in urban areas in Brazil.
Journal of aging and health 2009;21(1):3-37.
2009: John Vernon; Robert Goldberg; Joseph Golec
Economic evaluation and cost-effectiveness thresholds: signals to firms and implications for R & D investment and innovation.
PharmacoEconomics 2009;27(10):797-806.
2009: Joseph Golec; John Vernon
Financial risk of the biotech industry versus the pharmaceutical industry.
Applied health economics and health policy 2009;7(3):155-65.
2009: Joseph Cook; Graeme Hunter; John Vernon
The future costs, risks and rewards of drug development: the economics of pharmacogenomics.
PharmacoEconomics 2009;27(5):355-63.
2008: Joseph Golec; John Vernon
Measuring US pharmaceutical industry R&D spending.
PharmacoEconomics 2008;26(12):1005-17.
2008: Joseph P Cook; John Vernon; Richard Manning
Pharmaceutical risk-sharing agreements.
PharmacoEconomics 2008;26(7):551-6.
2007: Rexford E Santerre; John Vernon
Ownership form and consumer welfare: evidence from the nursing home industry.
Inquiry : a journal of medical care organization, provision and financing 2007;44(4):381-99.
2007: John Vernon
Perspectives on dynamic optimisation and control theory in treating hyperlipidaemia.
PharmacoEconomics 2007;25(7):533-5.
2007: John Vernon
Letter from the Commissioner's Office at the US FDA.
PharmacoEconomics 2007;25(4):267-8.
2007: John Vernon
Letter from the Commissioner's Office at the US FDA.
PharmacoEconomics 2007;25(2):89-90.
2007: John Vernon
Letter from the Commissioner's office at the US FDA.
PharmacoEconomics 2007;25(1):1-2.
2006: Rexford E Santerre; John Vernon
The consumer welfare implications of the hospital ownership mix in the US: an exploratory study.
Health economics 2006;15(11):1187-99.
2006: John Vernon; W Keener Hughen
A primer on dynamic optimization and optimal control in pharmacoeconomics.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2006;9(2):106-13.
2006: John Vernon
Letter from the commissioner's office at the US FDA.
PharmacoEconomics 2006;24(12):1179.
2006: John Vernon; Joseph H Golec; W Keener Hughen
The economics of pharmaceutical price regulation and importation: refocusing the debate.
American journal of law & medicine 2006;32(2-3):175-92.
2006: John Vernon; Scott J Johnson; W Keener Hughen; Antonio Jose Trujillo
Economic and developmental considerations for pharmacogenomic technology.
PharmacoEconomics 2006;24(4):335-43.
2005: Antonio Jose Trujillo; Jorge E Portillo; John Vernon
The impact of subsidized health insurance for the poor: evaluating the Colombian experience using propensity score matching.
International journal of health care finance and economics 2005;5(3):211-39.
2005: John Vernon; W Keener Hughen; Scott J Johnson
Mathematical modeling and pharmaceutical pricing: analyses used to inform in-licensing and developmental go/No-Go decisions.
Health care management science 2005;8(2):167-79.
2005: John Vernon
Examining the link between price regulation and pharmaceutical R&D investment.
Health economics 2005;14(1):1-16.
2004: Joseph H Golec; John Vernon
Pharmaceutical reimportation: the European experience--what the United States can expect.
Managed care (Langhorne, Pa.) 2004;13(6 Suppl):26-9; discussion 33-4, 41-2.